| |DECEMBER 20259CIPLA STEPS INTO REGENERATIVE MEDICINE WITH CIPLOSTEM KNEE OA THERAPYMOUNJARO BECOMES INDIA'S TOP-SELLING DRUG AT INR100 CRORECiplostem, launched today by Cipla in partnership with Stempeutics Research, signals a strong move into orthobiologic medicine.The new MSC therapy enters the market as India faces a fast-growing burden of knee osteoarthritis, now affecting more than 48.4 million people.Many patients rely on painkillers and physiotherapy, which offer only short-lived relief and do little to slow joint damage.Approved by the Drug Controller General of India, Ciplostem introduces an off-the-shelf, allogeneic treatment approach. Because the cells come from a donor rather than the patient, the therapy is ready for use without the wait of personalized preparation. This single-dose injection delivers 25 million cultured adult bone marrowderived mesenchymal stromal cells, paired with hyaluronic acid, directly into the affected knee.The Treatment is used for Grade II & III (knee OA) on the basis of its ability to reduce Inflammation, relieve Pain, and help maintain Cartilage at a Cellular Level. Therefore, this treatment would represent a Significant Transition from Symptomatic Therapies to Regenerative Therapies, to allow Providers and the Overall Industry, to focus on disease progression as opposed to just addressing symptoms of the disease.BN Manohar, MD and CEO of Stempeutics Research, emphasized the scientific depth behind the therapy, stating: "Ciplostem sets a new benchmark in regenerative medicine, reflecting years of dedicated research and robust Phase 3 evidence. We are pleased to partner with Cipla to extend the reach of this stem cell therapy in India, transforming scientific innovation into tangible patient impact."With this launch, Cipla positions Ciplostem as a high-value entrant in a market eager for advanced, long-acting treatment options for knee osteoarthritis. POGlobal pharma leader Lupin has taken a major step forward in the U.S. biosimilar market with a new exclusive licensing agreement for Armlupeg (pegfilgrastim-unne).The company announced today that it has partnered with Valorum Biologics, a U.S.-based biosimilar specialist, to drive the product's commercial launch and distribution across the country.Under this deal, Valorum will handle the U.S. commercialization strategy for Armlupeg, bringing its specialty-market expertise to expand the drug's reach. Lupin will continue to manufacture and supply the biosimilar while receiving an upfront licensing fee along with royalties tied to net sales."We are pleased to collaborate with Valorum to expand access to affordable treatment options for patients undergoing chemotherapy. This partnership reflects our unwavering commitment to improving patient outcomes and aligns with our mission to make high-quality biosimilars more accessible. We look forward to strengthening our presence in the US biosimilars market and building on our momentum as a global leader in developing and commercializing important biosimilar medicines," said Spiro Gavaris, president US Generics, Lupin."We are excited to launch Armlupeg (pegfilgrastim-unne) in the US. Our team has a proven track record in specialty markets, and we expect to capture significant market share through our commercial expertise," said Par S. Hyare, CEO of Valorum. "Crucially, we also look forward to providing another option for healthcare providers and patients, increasing access to this important treatment in oncology supportive care."Pegfilgrastim-unne is used to reduce the duration of neutropenia and lower the risk of febrile neutropenia in patients receiving chemotherapy. POImage Credit: cipla.com
<
Page 8 |
Page 10 >